<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="6456">Lidocaine</z:chebi> sensitive, repetitive atrial <z:hpo ids='HP_0001649'>tachycardia</z:hpo> is an unusual <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> whose electrophysiologic substrate remains undefined </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to analyze the electropharmacologic characteristics of this <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> with emphasis on its cellular substrate and response to drug challenges </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We retrospectively analyzed a series of 18 patients from an electrocardiographic and electrophysiologic perspective and the response to pharmacological challenge </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: There was no evidence of structural <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> in 12 patients, 4 patients presented with <z:hpo ids='HP_0000822'>systemic hypertension</z:hpo>; one patient had a prior <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and one a <z:hpo ids='HP_0001634'>mitral valve prolapse</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> depicted a consistent pattern in nine patients </plain></SENT>
<SENT sid="5" pm="."><plain>The first initiating ectopic beat showed a long coupling interval, the cycle length of the second <z:e sem="disease" ids="C0033036" disease_type="Disease or Syndrome" abbrv="">atrial ectopic beat</z:e> presented the shortest cycle length and a further prolongation was apparent towards the end of the atrial salvos </plain></SENT>
<SENT sid="6" pm="."><plain>Conversely, in the other nine cases, the atrial <z:hpo ids='HP_0001649'>tachycardia</z:hpo> cycle length was erratic </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> was suppressed by asynchronous atrial pacing at cycle lengths longer than those of the atrial <z:hpo ids='HP_0001649'>tachycardia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Intravenous <z:chebi fb="0" ids="6456">lidocaine</z:chebi> eliminated the <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> in <z:hpo ids='HP_0000001'>all</z:hpo> patients, but intravenous <z:chebi fb="1" ids="9948">verapamil</z:chebi> suppressed the atrial <z:hpo ids='HP_0001649'>tachycardia</z:hpo> in only two patients while <z:chebi fb="3" ids="16335">adenosine</z:chebi> caused a transient disappearance in 2/8 patients </plain></SENT>
<SENT sid="9" pm="."><plain>Only one patient responded to <z:hpo ids='HP_0000001'>all</z:hpo> the three agents </plain></SENT>
<SENT sid="10" pm="."><plain>Radiofrequency ablation was successfully performed in 10 patients </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Repetitive uniform atrial <z:hpo ids='HP_0001649'>tachycardia</z:hpo> can be sensitive to <z:chebi fb="0" ids="6456">lidocaine</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>In few cases, this rare focal <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> may be also suppressed by <z:chebi fb="3" ids="16335">adenosine</z:chebi> and/or <z:chebi fb="1" ids="9948">verapamil</z:chebi>, which suggests a diversity of electrophysiologic substrates that deserve to be accurately identified </plain></SENT>
</text></document>